ArticleFrontiers in nutrition2026
The effects of ketogenic diet and calorie-restricted diet on metabolic dysfunction-associated steatotic liver disease: a retrospective study.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent condition with limited established dietary therapies. Lifestyle modifications, particularly dietary adjustments, represent the primary therapeutic approach for MASLD. This study investigated the effects of ketogenic diet (KD) and calorie-restricted diet (CRD) on hepatic fat accumulation and metabolic parameters in MASLD patients. Methods: This retrospective cohort study analyzed 102 MASLD patients completing 12-week nutritional management (KD or CRD). FibroTouch, anthropometric, body composition, and laboratory parameters were assessed at baseline and week 12. Results: After 12 weeks, the KD group achieved a significantly greater reduction in CAP (ΔCAP) compared to the CRD group (median ΔCAP: 62.0 dB/m (IQR: 48.0-78.5) vs. 36.0 dB/m (IQR: 26.0-52.0); Conclusion: KD significantly reduced hepatic steatosis and fasting insulin versus CRD, with comparable weight loss but greater muscle loss warranting caution. These findings support KD as a promising MASLD intervention, requiring confirmation in larger trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.